Skip to content
Citation only via OpenAlex

Anti-cancer telomerase vaccines: Are they entering the age of maturity?

Gilberto Filaci

Journal of Vaccines & Vaccination · 2015

Abstract

T the enzyme synthesizing the telomeric regions of chromosomes, is considered a universal tumor associated antigen because expressed by the majority of cancers. The several clinical trials performed adopting telomerase as immunogen confirmed the safety of telomerase vaccination, but raised doubts concerning: a) the immunogenicity of telomerase; b) the capacity of telomerase vaccines of inducing clinical responses. The immunogenicity concerns have been now dispelled by demonstrations that: 1) telomerase is presented by tumor and antigen presenting cells; 2) ex vivo generated telomerasespecific CTL kill efficiently telomerase-expressing tumors; 3) circulating telomerase-specific T cells are present in 90% of cancer patients and, surprisingly, in 100% of healthy individuals, as observed in two our studies. These findings boost the search for a new generation of telomerase vaccines able to overcome the limits of their first generation. In this effort, our group recently completed a phase I/II trial in prostate and renal cancer patients with GX301, a new generation cancer vaccine. This multipeptidic vaccine includes four telomerase peptides, which bind promiscuously several HLA class I and II alleles allowing the coverage of the majority of HLA haplotypes and the induction of both helper and cytotoxic T cell responses. It also contains two adjuvants with complementary activities, making it able to efficiently activate both innate and adoptive immune responses. The results of a phase I/II trial, showing a 100% rate of telomerase-specific immune responses associated with evidences of clinical responses, suggest that innovative approaches may lead telomerase (and cancer) vaccination to an “age of maturity”.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
Canonical
link ↗
Fetched
2026-10-10 MST

Cite this

APA
Filaci, G. (2015). Anti-cancer telomerase vaccines: Are they entering the age of maturity?. <em>Journal of Vaccines & Vaccination</em>. https://openalex.org/W2557721545
Vancouver
Filaci G. Anti-cancer telomerase vaccines: Are they entering the age of maturity?. Journal of Vaccines & Vaccination. 2015.
BibTeX
@article{gilberto2015Antica, title = {Anti-cancer telomerase vaccines: Are they entering the age of maturity?}, author = {Gilberto Filaci}, journal = {Journal of Vaccines & Vaccination}, year = {2015}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings